Product Name: Akt2 (135-149)
Product Number: PE-01AWP99
| Size: | 200 µg | Price: | 51.00 | |
| 1 mg | $US | 102.00 | ||
| 5 mg | 224.00 |
Peptide Name: Akt2 (135-149)
Product Use: Services as a blocking peptide for use with the Akt2-1 rabbit polyclonal antibody (Cat. No.: AB-NK130-4) that is also available from Kinexus. The peptide sequence is located in the pre-kinase catalytic domain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CEMEVAVSKARAKVTM
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1752.1 Da
Peptide Purity Percent after Synthesis and Purification: >95
Product Use: Services as a blocking peptide for use with the Akt2-1 rabbit polyclonal antibody (Cat. No.: AB-NK130-4) that is also available from Kinexus. The peptide sequence is located in the pre-kinase catalytic domain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CEMEVAVSKARAKVTM
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1752.1 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Akt2 pan-specific antibody (Cat. No.: AB-NK130-4)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Akt2 pan-specific antibody (Cat. No.: AB-NK130-4)
Scientific Background: Akt2 (PKBB, PRKBB) is a protein-serine/threonine kinase of the AGC group and Akt family. Its cell signalling activities involve activating cell surival and proliferation, increasing metabolism, and angiogenesis. Its interaction network contains over 100 substrates which includes inhibiting p53 via downstream signalling, activating mTOR, inhibition of GSK3b, and inhibition of cyclins .Phosphorylation of T309 and S474 increases phosphotransferase activity. Cancer-related mutations in human tumours point to a gain of function of the protein kinase. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis. The active form of the protein kinase normally acts to promote tumour cell proliferation. In many cancers, Akt2 is found to be overexpressed and amplified. It is also linked with invasion, cell migration and induction of angiogenesis. It is important in cell survival regulation, insulin signalling, angiogenesis and tumour formation. Defects in Akt2 contributes to suspectibility to breast cancer and the malignancy of a subset of human ductal pancreatic cancer. Akt2 promotes metastasis of tumour cells, but does not affect the latency of tumour development. Together with Akt3, it has a critical role in glioblastomas. However, there are no prominent mutations in Akt2 in human cancers, with a relatively dispersed pattern of low level mutations through out the full length of the protein. In cancer, it is found to be overexpressed and amplified. It is also linked with invasion, cell migration and induction of angiogenesis.
© Kinexus Bioinformatics Corporation 2017